Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 25, 2004. The document primarily reports on share repurchase activities authorized by shareholders at the Annual General Meeting on May 17, 2004, and updates regarding directors' interests in company shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes and executive compensation movements.
- Share Repurchases: The Company purchased a total of 2,095,000 Ordinary Shares across three transactions in late May 2004.
- Treasury Holdings: Following the final transaction on May 25, the Company held 14,827,000 shares in treasury.
- Shares in Issue: Excluding treasury shares, 5,918,588,074 shares were in issue as of May 25, 2004.
- Transaction Prices: Repurchase prices ranged from 1,150.2611 pence to 1,179.78 pence per share.
Material Changes
The primary material change reported is the reduction in outstanding shares due to the buyback program and the corresponding increase in treasury stock.
- May 20, 2004: Purchased 845,000 shares at 1,179.78 pence. Treasury holdings rose to 13,577,000.
- May 24, 2004: Purchased 450,000 shares at 1,157.223 pence. Treasury holdings rose to 14,027,000.
- May 25, 2004: Purchased 800,000 shares at 1,150.2611 pence. Treasury holdings rose to 14,827,000.
- Directors' Interests: Notional increases in ADR holdings for Directors Dr. J.P. Garnier and Dr. T. Yamada, and Ordinary Shares for Mr. J.D. Coombe, occurred due to dividend reinvestment in the Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a procedural disclosure of share transactions and director interest updates. The text explicitly states that the announcements do not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares repurchased (2,095,000) against the company's authorized buyback limit from the May 17, 2004 AGM.
- Confirm the final count of shares in issue (5,918,588,074) and treasury shares (14,827,000) in subsequent filings.
- Review the impact of the share buybacks on earnings per share (EPS) in the next quarterly or annual report.
- Check the vesting schedule and performance metrics for the Performance Share Plan affecting Directors Garnier, Yamada, and Coombe.